Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A
Open Access
- 23 April 2015
- journal article
- research article
- Published by Elsevier BV in Journal of Thrombosis and Haemostasis
- Vol. 13 (6), 967-977
- https://doi.org/10.1111/jth.12911
Abstract
No abstract availableFunding Information
- Biogen Idec
This publication has 37 references indexed in Scilit:
- Inhibitor development in previously treated hemophilia A patients: a systematic review, meta‐analysis, and meta‐regressionJournal of Thrombosis and Haemostasis, 2013
- Results from a large multinational clinical trial (guardian™3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokineticsHaemophilia, 2013
- Biochemical and functional characterization of a recombinant monomeric factor VIII–Fc fusion proteinJournal of Thrombosis and Haemostasis, 2013
- Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patientsBlood, 2012
- Treatment trends for haemophilia A and haemophilia B in the United States: results from the 2010 practice patterns surveyHaemophilia, 2012
- Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia BNew England Journal of Medicine, 2011
- Comparative pharmacokinetics of plasma‐ and albumin‐free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age‐related differences and implications for dose tailoringJournal of Thrombosis and Haemostasis, 2010
- Factor VIII and von Willebrand factor interaction: biological, clinical and therapeutic importanceHaemophilia, 2009
- Quantitation of anti–factor VIII antibodies in human plasmaBlood, 2009
- Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe HemophiliaNew England Journal of Medicine, 2007